These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 4058753)

  • 21. [Comparison of administration of low doses of bromocriptine and levodopa in the early treatment of Parkinson disease].
    Sternić N; Kostić V
    Srp Arh Celok Lek; 1992; 120(1-2):1-5. PubMed ID: 1641693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parkinson's disease: a comparison of mesulergine and bromocriptine.
    Burton K; Larsen TA; Robinson RG; Bratty PJ; Martin WR; Schulzer M; Calne DB
    Neurology; 1985 Aug; 35(8):1205-8. PubMed ID: 3895033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bromocriptine and domperidone in the treatment of Parkinson disease.
    Quinn N; Illas A; Lhermitte F; Agid Y
    Neurology; 1981 Jun; 31(6):662-7. PubMed ID: 7195483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of bromocriptine in methyldopa treated hypertension.
    Lewis MJ; Henderson AH
    Br J Clin Pharmacol; 1980 Jan; 9(1):57-60. PubMed ID: 6986893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combined treatment of the early stages of Parkinson's syndrome with bromocriptine and levodopa. The results of a multicenter study].
    Fischer PA; Przuntek H; Majer M; Welzel D
    Dtsch Med Wochenschr; 1984 Aug; 109(34):1279-83. PubMed ID: 6381019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
    Goetz CG; Tanner CM; Glantz RH; Klawans HL
    Neurology; 1985 May; 35(5):749-51. PubMed ID: 3990974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.
    Riopelle RJ; Gawel MJ; Libman I; King DB; McLean DR; Paulseth R; Raphy B; Bouchard S
    Eur Neurol; 1988; 28 Suppl 1():11-4. PubMed ID: 3288477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension.
    Mehdirad A; Karabin B; Gupta F
    Clin Auton Res; 2017 Jul; 27(Suppl 1):25-27. PubMed ID: 28634637
    [No Abstract]   [Full Text] [Related]  

  • 29. [Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study].
    Montastruc JL; Rascol O; Rascol A
    Rev Neurol (Paris); 1990; 146(2):144-7. PubMed ID: 2181588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study.
    Staal-Schreinemachers AL; Wesseling H; Kamphuis DJ; vd Burg W; Lakke JP
    Neurology; 1986 Feb; 36(2):291-3. PubMed ID: 3511405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
    Montastruc JL; Rascol O; Senard JM; Rascol A
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1034-8. PubMed ID: 8089666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical assessment of therapeutic results of Ergolactyn (bromocriptine) in Parkinson's disease].
    Kuran W; Kulczycki J
    Neurol Neurochir Pol; 1993; 27(4):507-13. PubMed ID: 8247238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine.
    Demonet JF; Rostin M; Dueymes JM; Ioualalen A; Montastruc JL; Rascol A
    Clin Neuropharmacol; 1986; 9(2):200-1. PubMed ID: 3708605
    [No Abstract]   [Full Text] [Related]  

  • 34. [Efficacy and safety of ropinirole in the treatment of Parkinson's disease: a multi-center, randomized, double-blind and bromocriptine-controlled trial].
    Li SH; Chen HB; Wang ZF; Tang RH; Zhang XY; Yang JS; Zhao WQ; Sun XR; Ma J
    Zhonghua Yi Xue Za Zhi; 2013 Jul; 93(25):1952-7. PubMed ID: 24169242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
    Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M
    Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
    Schneider E; Hubener K; Fischer PA
    Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.
    Factor SA; Sanchez-Ramos JR; Weiner WJ
    J Neurol Neurosurg Psychiatry; 1988 Apr; 51(4):529-33. PubMed ID: 3288717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
    Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
    Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
    Hauser RA; Holford NH
    Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose, slow-increase bromocriptine in patients with progressive Parkinson's disease and complications of levodopa therapy.
    Stern MB; Vernon GM; Gollomp SM; Hurtig HI
    Bull Clin Neurosci; 1986; 51():52-6. PubMed ID: 3455244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.